Combination PARP and Topoisomerase I Inhibitor Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer chemotherapy treatments using topoisomerase I inhibitors and PARP inhibitors often show limited efficacy, as they typically target cancer cells alone, and there is a need for combination strategies that enhance treatment outcomes.
Innovation Solution
Administering a PARP-inhibiting amount of a PARP inhibitor and a topoisomerase I-inhibiting amount of a long-acting topoisomerase I inhibitor, either sequentially or simultaneously, to synergistically target cancer cells, with the option of varying administration schedules and doses to optimize treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If a single antineoplastic agent is used for cancer treatment, then the treatment regimen is simple and ease of administration is maintained, but the efficacy and treatment outcomes are limited
Solution Approach 1:
The patent combines two different antineoplastic agents (a topoisomerase I inhibitor and a PARP inhibitor) into a single treatment regimen. This merging of mechanisms of action allows the therapy to target cancer cells through multiple pathways simultaneously, improving overall efficacy while managing the complexity through a coordinated dosing schedule
2Productivity
If combination therapy with multiple antineoplastic agents is used, then treatment efficacy and tumor regression are enhanced, but the complexity of administration and dosing increases
Solution Approach 1:
The patent employs periodic action by establishing a specific dosing schedule where the topoisomerase I inhibitor is administered on Day 1 and the PARP inhibitor is administered on Day 8. This periodic sequencing allows each agent to be given at optimal intervals to maximize synergistic effect while maintaining administrative feasibility through clear scheduling guidelines
3Productivity
If higher doses of antineoplastic agents are administered, then treatment effectiveness is improved, but side effects and toxicity increase
Solution Approach 1:
The patent applies parameter changes by optimizing the dosing parameters of each agent rather than simply increasing the total dose. By adjusting the timing, frequency, and specific dosage amounts of the topoisomerase I inhibitor and PARP inhibitor, the regimen achieves enhanced effectiveness while minimizing toxicities through precise parameter optimization
Data Source
AI summary
The invention relates to (among other things) a method comprising the steps of (a) administering to a patient a PARP-inhibiting amount of a PARP inhibitor; and (b) administering to the patient a topoisomerase I-inhibiting amount of a long-acting topoisomerase I inhibitor.